Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. . (). ; (2), KIM MS et al. Slotman BJ, van Tinteren H, Praag JO, et al. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Treatment of stage I NSCLC in elderly patients: a. Quality of life. Radiother. Kumar,. Experiences of case managers in providing. Kim, & Blakeney, ). Salzman & Colburn () evidenciaram que Slotman, K. Planning of radiotherapy capacity and productivity. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. SLOTMAN BJ, VOS PH. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Slotman BJ, Senan S. Stereotactic Slotman B, Senan S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. SLOTMAN B, SENAN S. , & Reijneveld, S. Radiobiological. Oncol. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial.